Aprea Announces 58 New Patents for Oncology Drugs
Aprea Therapeutics added 58 new patents covering its WEE1 and ATR inhibitors to its oncology portfolio. The expansion strengthens the company's intellectual property, protecting its clinical assets and accelerating its precision medicine development pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day